Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/1999
08/10/1999US5935814 G-protein coupled receptor family polypeptides, referred to as hfgan72y, altered nucleic acid seqences encoding it and recombinant materials and methods for its production; use in design of protocols and treatment of various infections
08/10/1999US5935813 Human pancreatitis-associated protein
08/10/1999US5935812 Polynucleotide
08/10/1999US5935810 Polynucleotide sequences coding a human weight regulatory protein; therapy and diagnostic tool for eating disorders cachexia; antisense agents; gene therapy
08/10/1999US5935803 Methods to identify immunomodulators using cognate interaction of PKC-theta
08/10/1999US5935798 Assay for YKL-40 as a marker for degradation of mammalian connective tissue matrices
08/10/1999US5935795 Glial cell line-derived neurotrophic factor antibody
08/10/1999US5935786 Methods for analyzing PRLTS DNA
08/10/1999US5935776 Small molecule inhibition of RNA/ligand binding
08/10/1999US5935605 Oral preparation for patients with chronic renal insufficiency, method of making and use
08/10/1999US5935601 Acylated peptide as a carrier for oral administration
08/10/1999US5935593 Chemo-mechanical expansion delivery system
08/10/1999US5935586 Therapeutic/cosmetic compositions comprising CGRP antagonists for treating disease states of the skin
08/10/1999US5935583 A vaccine strain of giardia which is cultured in media containing bile so as to produce a toxin in vitro for preventing or treating intestinal protozoal infections in an animal
08/10/1999US5935579 A peptide will stimulate proliferation of a t-cell clone in a t-cell proliferation assay and produce an alloepitopic effect, peptide when administered in a tolerizing amount will suppress proliferation of t-cell clone in second assay
08/10/1999US5935578 Contraceptive vaccine
08/10/1999US5935577 Treatment of autoimmune disease using tolerization in combination with methotrexate
08/10/1999US5935576 Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
08/10/1999US5935575 Interleukin-4 stimulated T lymphocyte cell death for the treatment of allergic disorders
08/10/1999US5935572 Composition containing protease separate from glycosidase for removing nits in treating lice infestation
08/10/1999US5935570 Infecting a plant with a genetically transformed clavibacter that can synthesize a bioactive polypeptide, such as a rabies polypeptide; culturing the microorganism in the plant, oral administration of polypeptide to a mammal; vaccines
08/10/1999US5935568 Gene therapy for effector cell regulation
08/10/1999US5935567 Administering a polypeptide ip-10, or a suitable dna vector encoding the polypeptide ip-10
08/10/1999US5935566 Stable aqueous alfa interferon solution formulations
08/10/1999US5935565 Method for increasing the level of stem cells in peripheral blood
08/10/1999US5935564 Use of hydrophobic interaction chromatography to purify polyethylene glycols
08/10/1999US5935437 Preparation of autologous plasma and fibrin gel
08/10/1999CA2093434C Regulation of immunoglobulin production by interleukin-9
08/10/1999CA2070882C A process for large-scale production of antimicrobial peptide in high purity
08/10/1999CA2049449C Hla-dr antigen gene and its nucleotide sequence and its use
08/10/1999CA1340704C Human interferon-gamma, process to prepare said human interferon-gamma, and its use
08/10/1999CA1340703C Production of insulin-like growth factor binding protein
08/10/1999CA1340702C Derivatives of soluble t-4
08/10/1999CA1340698C Preparation and uses of interferon-gamma
08/09/1999CA2260450A1 Process for the production of alkoxycarbonyldipeptides intermediates in the synthesis of the lisinopril
08/09/1999CA2245999A1 Novel compounds
08/05/1999WO1999038992A1 Synergism between thymidine kinase gene therapy and topoisomerase i and topoisomerase ii inhibitors
08/05/1999WO1999038987A1 METHOD FOR PRODUCING, BY PLANT CELLS, α1-ANTITRYPSIN AND ITS ALLELES, AND PRODUCTS CONTAINING THE RESULTING α1-ANTITRYPSIN
08/05/1999WO1999038983A1 Novel sphingosine-1 phosphate lyase
08/05/1999WO1999038981A2 Human protein kinase molecules
08/05/1999WO1999038978A1 Methods and reagents for decreasing allergic reactions
08/05/1999WO1999038974A1 EQUINE Fc EPSILON RECEPTOR ALPHA CHAIN NUCLEIC ACID MOLECULES, CORRESPONDING PROTEINS AND USES THEREOF
08/05/1999WO1999038973A2 Compounds for therapy and diagnosis of lung cancer and methods for their use
08/05/1999WO1999038971A1 Protein binding to midkine
08/05/1999WO1999038969A1 PROTEIN HUMAINE β-TrCP
08/05/1999WO1999038968A1 Recombinant proteins from hgf and msp
08/05/1999WO1999038967A2 Recombinant proteins derived from hgf and msp
08/05/1999WO1999038965A1 Human hairless gene, protein and uses thereof
08/05/1999WO1999038964A2 Promoter regions of the mouse and human telomerase rna component genes
08/05/1999WO1999038963A1 Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
08/05/1999WO1999038958A1 SUBSTRATE ANALOGS FOR MurG, METHODS OF MAKING SAME AND ASSAYS USING SAME
08/05/1999WO1999038955A2 Mutant herpes simplex viruses and uses thereof
08/05/1999WO1999038891A1 Multimeric erythropoietin with altered biological activity
08/05/1999WO1999038890A1 Erythropoietin with altered biological activity
08/05/1999WO1999038889A2 Modulation of sodium channels in dorsal root ganglia
08/05/1999WO1999038888A2 Peptide inhibitors of the serine protease activity associated to the ns3 protein of hcv, relevant uses and process of production
08/05/1999WO1999038882A1 Human cystatin f
08/05/1999WO1999038881A1 67 human secreted proteins
08/05/1999WO1999038880A1 Genetic immunization with nonstructural proteins of hepatitis c virus
08/05/1999WO1999038546A1 Hydrophilic coating for an intracorporeal medical device
08/05/1999WO1999038545A1 Lubricious hydrophilic coating for an intracorporeal medical device
08/05/1999WO1999038536A1 Absorbable microparticles
08/05/1999WO1999038535A1 Process for making absorbable microparticles
08/05/1999WO1999038531A1 TREATING ATOPIC DERMATITIS WITH IgE ANTAGONISTS
08/05/1999WO1999038527A1 Spray drying of pharmaceutical formulations containing amino acid-based materials
08/05/1999WO1999038526A1 Variant peptide ligands that selectively induce apoptosis
08/05/1999WO1999038525A1 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
08/05/1999WO1999038524A2 Therapeutic administration of low density lipoprotein receptor for viral infections and immune regulation
08/05/1999WO1999038523A1 CYTOKINE INDUCERS COMPRISING M161Ag
08/05/1999WO1999038501A2 Method of regulating glucose metabolism, and reagents related thereto
08/05/1999WO1999038495A2 Controlled release delivery of peptide or protein
08/05/1999WO1999038380A1 Improved extracorporeal methods for enhancing antigen presentation and immune responsiveness
08/05/1999WO1999029718A3 Bone morphogenetic protein (bmp)-17 and bmp-18 and compositions thereof
08/05/1999WO1999028474A3 Chemokine variants and methods of use
08/05/1999WO1999028341A3 Maintenance of smooth muscle integrity by morphogenic proteins
08/05/1999WO1999027096B1 A NOVEL EGF MOTIF PROTEIN OBTAINED FROM A cDNA LIBRARY OF FETAL LIVER-SPLEEN
08/05/1999WO1999025843A3 Human checkpoint kinase, hcds1, compositions and methods
08/05/1999WO1999024559A3 Nuclear targeting by means of streptococcal protein h
08/05/1999WO1999022763A3 Encapsulated immunomodulators useful as vaccine adjuvants
08/05/1999WO1999021541A3 Amelioration of ischemic damage using synthetic oxygen carriers
08/05/1999WO1999020645A9 Vesicular amino acid transporter composition and method
08/05/1999WO1999020643A9 Using polyamide nucleic acid oligomers to engender a biological response
08/05/1999WO1999020121A9 Methods for obtaining protein mixtures and control factors from wound granulation, epithelialization or determined blastocyst tissue
08/05/1999WO1999019359A8 Cellular receptor for hiv-1 vpr essential for g2/m phase transition of the cell cycle
08/05/1999WO1999019357A3 Cell regulatory genes, encoded products, and uses related thereto
08/05/1999WO1999018206A3 Human cancer antigen ny eso-1/cag-3 and gene encoding same
08/05/1999WO1999017740A9 Peptide/lipid complex formation by co-lyophilization
08/05/1999WO1999014322A3 Allelic variant of human stat3
08/05/1999WO1999011292A9 Compositions and methods for treating arthritis utilizing gene therapy
08/05/1999WO1999009216A9 Highly sensitive multimeric nucleic acid probes
08/05/1999WO1999006059A3 Methods and compositions relating to no-mediated cytotoxicity
08/05/1999WO1998024812A3 A6la5a12 polypeptides and polynucleotides and methods of use therefor
08/05/1999WO1997016206A8 Bladder nuclear matrix proteins and their use in detecting and treating cell proliferative disorders
08/05/1999WO1995031429A8 Photocleavable agents and conjugates for the detection and isolation of biomolecules
08/05/1999DE19803353A1 Use of interleukin-4 to prepare medicament to lower increase of interferon-gamma concentration in blood during stress situations in multiple sclerosis patients
08/05/1999CA2819705A1 Method of regulating glucose metabolism, and reagents related thereto
08/05/1999CA2755452A1 Method of regulating glucose metabolism, and reagents related thereto
08/05/1999CA2362320A1 Human hairless gene, protein and uses thereof
08/05/1999CA2320228A1 Substrate analogs for murg, methods of making same and assays using same
08/05/1999CA2319710A1 Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
1 ... 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2511 ... 3163